The study of H.pylori third line eradication therapy using Vonoprazan

The study of H.pylori third line eradication therapy using Vonoprazan - The study of H.pylori third line eradication therapy using Vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024290

Enrollment

Registered

2016-10-05

Start date

2016-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

vonopurazan+metoronidazole(MNZ)+sitafloxacin(STFX)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First line eradication(PPI+AMPC+CAM)and second line eradication(PPI+AMPC+MNZ)failure patients with H.pylori infection who want to take eradication treatment. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy or lactation. Past history of allergy for the drugs used in this therapy . Sever liver dysfunction, sever renal dysfunction, sever heart dysfunction. Patients who are disqualified for the sutdy by physicians.

Design outcomes

Primary

Measure	Time frame
Related study with eradication results,antimicrobial drug resisutance and H.pylori gene in H.pylori third line eradication therapy	—

Secondary

Measure	Time frame
To evaluate safety of H.pylori third line eradication therapy	—

Countries

Japan

Contacts

Public ContactInoue/Eguchi Syuji / Sizuka

National Hospital Organization National Kochi Hospital gstroenterology

inoue.shuji.cs@mail.hosp.go.jp088-844-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026